

OIPE JC173
 JUN 08 2001
 PATENT & TRADEMARK OFFICE

PATENT APPLICATION

ATTORNEY'S DOCKET NO. A-423C
GROUP ART UNIT 1646
Serial No. 09/284,100
Filing Date April 7, 1999
Examiner S. Prasad

In Re Application of Narhi et al.
For KERATINOCYTE GROWTH FACTOR-2 PRODUCTS

TO THE ASSISTANT COMMISSIONER FOR PATENTS:
☒ Applicants request the following extension of time under 37 CFR 1.136(a):
☐ One month of original due date (\$110.00)
☐ Two months of original due date (\$390.00)
☒ Three months of original due date (\$890.00)
☐ Four months of original due date (\$1,390.00)
☐ Five months of original due date (\$1,890.00)
☒ A response in connection with the matter for which this extension is requested:
☒ is filed herewith.
☐ has been filed.
☐ The response is the filing of a continuing prosecution application, the prior application having an express abandonment conditioned on the granting of a filing date to the continuing application.
☒ The accompanying papers include amended claims for which no additional fee is required.
☐ The accompanying papers include amended claims the fee for which has been calculated as follows:

RECEIVED
 JUN 11 2001
 TECH CENTER 1600/2900

CLAIMS AS AMENDED						
(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims remaining After amendment		Highest number Previously paid for	No. of Extra claims present	Rate	Additional Fee
Total Claims	*	Minus	**	= 0	x \$18	= \$ 0.00
Indep. Claims	*	Minus	***	= 0	x \$80	= 0.00
					+ \$270	= 0.00

☐ First Appearance of a multiple dependent claim
Total Additional Fee for this Amendment \$0.00

* If the entry in column 2 is less than the entry in column 4, write "0" in column 5.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.
 The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col 1. of a prior amendment or the number of claims originally filed.

☐ The following other fees are incurred by the accompanying papers.
☐ Other: _____
 Please charge Deposit Account No. 01-0519 in the name of Amgen Inc. in the amount of \$890.00.

A duplicate copy of this petition is attached.

☒ If an additional extension of time is required, please consider this a request therefore.
☒ The Commissioner is hereby authorized to charge any additional fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 01-0519.

Please Send Future Correspondence To:
 US Patent Operations/TDZ
 Dept. 4300, M/S 27-4-A
 AMGEN INC.
 One Amgen Center Drive
 Thousand Oaks, California 91320-1799

Thomas B. Zindrick
 Attorney/Agent for Applicant(s)
 Registration No.: 32,185
 Phone: (805) 447-8101
 Date: June 5, 2001
 Ref: 00000001 DAK: 010519 09284100

01 FC:117
 890.00 CH


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

June 5, 2001
 Date

Ronda G. Spahr
 RONDA G. SPAHR

COPY



CERTIFICATE OF MAILING: I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.	
(Sign here) <i>Ronda G. Spahr</i>	June 5, 2001
(Print Name) RONDA G. SPAHR	(Date)

#10/c
BP
6-11

Patent Application

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Narhi et al.

Art Unit No.: 1646

Serial No.: 09/284,100

Examiner: S. Prasad

Filed: April 7, 1999

For: KERATINOCYTE GROWTH FACTOR-2
PRODUCTS

Docket No.: A-423C

RECEIVED

JUN 11 2001

TECH CENTER 1600/2

Assistant Commissioner for Patents
Washington, D. C. 20231

RESPONSE AND AMENDMENT

The following paper is being submitted in response to an Office Action dated December 5, 2000. Please amend this application as follows:

In the Claims

Please replace claims 13-16, 18, 21-22 and 25 with the following:

13. (Amended) A method comprising culturing the host cell of Claim 12 in a suitable nutrient medium.

14. (Amended) The method according to Claim 13, wherein said host cell is an *E. coli* cell.

15. (Amended) The method according to Claim 13, wherein said host cell is selected from a baculovirus cell, COS cell or Chinese hamster ovary cell.